Current Report Filing (8-k)
October 11 2016 - 5:02PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date
of earliest event reported): October 5, 2016
OptimizeRx Corporation
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-53605
|
|
26-1265381
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
400
Water Street, Suite 200, Rochester, MI
|
|
48307
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
248-651-6568
|
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION 8 – Other Events
On October 5, 2016, we issued a press release concerning the acquisition
of the LogRx inventory for the remainder of 2016 and 2017 from Allscripts Healthcare, LLC. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
Item 9.01
|
Financial Statements and Exhibits
|
99.1
|
Press release, dated October 5, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OptimizeRx Corporation
/s/
Doug Baker
|
|
Doug Baker
Chief Financial Officer
|
|
|
|
Date: October 11, 2016
|
|
3
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024